This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
HCA Healthcare price target raised to $555 from $525 at RBC Capital
RBC Capital raised the firm’s price target on HCA Healthcare (HCA) to $555 from $525 and keeps an Outperform rating on the shares. The firm was “pleased” to see a strong reaction in shares after a solid Q4 result and strong initial 2026 guidance, the analyst tells investors in a research note. The 2026 full year outlook reflects better than expected core performance as well as $400M in savings from resiliency efforts that more than offset the ePTC expiry and lower contribution from state supplemental programs, RBC added.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
Disclaimer & DisclosureReport an Issue
- HCA Healthcare price target raised to $529 from $490 at TD Cowen
- HCA Healthcare price target raised to $598 from $525 at UBS
- HCA Healthcare price target raised to $540 from $500 at Oppenheimer
- HCA Healthcare price target raised to $588 from $525 at Cantor Fitzgerald
- HCA Healthcare price target raised to $550 from $500 at KeyBanc
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
